ClinicalTrials.gg
CompletedNCT00642512Updated Apr 3, 2008

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

A Phase 3 interventional study of dronabinol and ondansetron in Chemotherapy Induced Nausea and Vomiting, sponsored by Solvay Pharmaceuticals. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-03.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 286 studies in Vomiting with a site in United States — 26 open to participants now, 29 under way, 5 of them phase 3. Vomiting · United States.

Enrollment
144th of 256
64 · median 89
Started
2003
with 8 others
Phase 3
48 of 286
2 open now
Registered
68th of 286
by date

Among the 286 studies in Vomiting with a site in United States, this one is the 144th largest by enrollment of the 256 interventional ones that give a count, is one of 9 that started in 2003, is one of 48 in phase 3, and was the 68th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

26 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Vomiting with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.

03

Conditions studied

  • Chemotherapy Induced Nausea and Vomiting

Browse trials for

Keywords

  • CINV
  • chemotherapy
  • nausea
  • vomiting
  • retching
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological evidence of non-CNS (primary or disease) and lymphomas which are not involving the bone marrow.
  • Undergoing single or multiple days of chemotherapy as long as Day 1 chemotherapy includes:

    1. a moderate-to-high emetogenic regimen, or
    2. oxaliplatin at doses employed for treatment of colon cancer, or
    3. the combination of AC [AdriamycinÒ (60 mg/m2) with cyclophosphamide (600 mg/m2)] as to be used for the chemotherapeutic drug regimen involving taxanes in the treatment of breast cancer.

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy agents falling into the low (Level 1), moderate-to-low (Level 2), moderate (Level 3) unless used in combination with a Level 4 chemotherapy agent on Day 1 of the study.
  • Chemotherapy agents falling into the high (Level 5) classification during study.
  • Any combination of chemotherapy agents that does not fall into the moderate-to-high (Level 4) classification
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    1

    Drug: dronabinol

  • Active comparator
    2

    Drug: ondansetron

  • Other
    3

    Drug: dronabinol/ondansetron

  • Placebo comparator
    4

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Total response of nausea and vomiting/retching was defined as no vomiting and/or retching, an intensity of nausea of < 5 mm on the visual analog scale (VAS) and no use of rescue medication.

    Time frame: 5 days

Secondary outcomes

  1. Complete responder rate (no vomiting/retching, intensity of nausea of ≤ 30 mm on the VAS and no use of rescue medication)

    Time frame: 5 days

  2. Presence or absence of nausea

    Time frame: 5 days

  3. Episodes of vomiting and/or retching

    Time frame: 5 days

  4. Duration of nausea and vomiting and/or retching

    Time frame: 5 days

07

Study locations

43 sites
  • Site 970
    Tucson, Arizona, United States
  • Site 950
    Anaheim, California, United States
  • Site 925
    Fountain Valley, California, United States
  • Site 913
    Greenbrae, California, United States
  • Site 909
    Los Angeles, California, United States
  • Site 908
    Pomona, California, United States
  • Site 943
    Rancho Mirage, California, United States
  • Site 932
    Boynton Beach, Florida, United States
  • Site 924
    Hollywood, Florida, United States
  • Site 940
    Lakeland, Florida, United States
  • Site 921
    New Port Richey, Florida, United States
  • Site 929
    New Port Richey, Florida, United States
  • Site 933
    Ormond Beach, Florida, United States
  • Site 922
    Marietta, Georgia, United States
  • Site 928
    Harvey, Illinois, United States
  • Site 914
    Orland Park, Illinois, United States
  • Site 926
    Skokie, Illinois, United States
  • Site 946
    Springfield, Illinois, United States
  • Site 956
    Terre Haute, Indiana, United States
  • Site 905
    Southfield, Michigan, United States
  • Site 916
    Fergus Falls, Minnesota, United States
  • Site 937
    Greenwood, Mississippi, United States
  • Site 958
    St. Louis, Missouri, United States
  • Site 904
    Missoula, Montana, United States
  • Site 919
    Little Silver, New Jersey, United States
  • Site 920
    Voorhees, New Jersey, United States
  • Site 910
    Bronx, New York, United States
  • Site 948
    Brooklyn, New York, United States
  • Site 953
    Brooklyn, New York, United States
  • Site 949
    Valhalla, New York, United States
  • Site 947
    Wilmington, North Carolina, United States
  • Site 902
    Bismarck, North Dakota, United States
  • Site 942
    Fargo, North Dakota, United States
  • Site 944
    Columbus, Ohio, United States
  • Site 934
    Oklahoma City, Oklahoma, United States
  • Site 931
    Philadelphia, Pennsylvania, United States
  • Site 906
    Pittsburgh, Pennsylvania, United States
  • Site 918
    Charleston, South Carolina, United States
  • Site 923
    N. Charleston, South Carolina, United States
  • Site 917
    Chattanooga, Tennessee, United States
  • Site 939
    Chattanooga, Tennessee, United States
  • Site 915
    Texarkana, Texas, United States
  • Site 951
    Arlington, Virginia, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Jul 2003
Primary completionActual
Jul 2004
CompletionActual
Jul 2004
Last update
Apr 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00642512
First posted
Mar 25, 2008
Start date
Jul 2003
Primary completion
Jul 2004
Completion
Jul 2004
Last update
Apr 3, 2008

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion